Clinical Trial Detail

NCT ID NCT04065399
Title A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Syndax Pharmaceuticals
Indications

acute myeloid leukemia

acute lymphoblastic leukemia

Therapies

SNDX-5613

Age Groups: senior adult

Additional content available in CKB BOOST